Freedom to Operate

Every 30 minutes, a MedTech patent application lands on the desk of the European Patent Office. In this relentless tide of innovation, Freedom to Operate (FTO) is the difference between bringing life-saving technology to market or watching millions in development costs sink beneath patent litigation.
The medical technology landscape has become a patent minefield. One wrong step can trigger injunctions that halt product launches, licensing demands that cripple profit margins, and courtroom battles that drain resources meant for patient care. Yet so many MedTech companies treat this analysis as an afterthought.

Lock in early

Filing a provisional patent application will be your first line of defence. This initial filing establishes priority date, with your temporal claim to an innovation that could prove decisive when competitors emerge with similar solutions. The provisional route offers a twelve-month window to refine inventions, conduct market research, and file complete applications. During this critical period, you maintain confidentiality while building evidence of commercial viability. For resource-conscious startups, it's an efficient way to secure intellectual property rights without the full cost of complete patent prosecution.

But timing requires surgical precision. File too early with incomplete technology, and you risk narrow protection that leaves obvious improvements unguarded. Wait too long, and competitors might establish prior art or file competing applications. The optimal moment will capture core functionality, while preserving flexibility for iterative development.

Mapping competitor territory

Live competitor patents represent immediate threats requiring systematic analysis. Established MedTech companies maintain extensive patent portfolios designed to create defensive moats around their core technologies. These granted patents carry enforcement power with the legal authority to block competing products through injunctions or licensing demands.

Effective competitor mapping requires understanding patent families across key markets. A single invention might spawn dozens of related applications, each targeting specific technological aspects or geographic territories. Patent landscaping reveals claim scope, prosecution history, and potential invalidity arguments essential for navigation planning.

Professional patent searching tools will help identify relevant patents, but human expertise remains irreplaceable for interpreting claim language and assessing real-world infringement risk. The goal isn't finding every potentially relevant patent. So, focus on patents from key competitors, core technology areas, and markets where enforcement seems likely.

Pending applications

Published applications represent future uncertainty that can mature into enforcement risks. These filings remain in prosecution, potentially expanding or narrowing in scope before grant. The eighteen-month publication delay means any recent competitor activity will remain invisible until after critical development decisions have been made.

International patent classification codes provide structured search frameworks, but classification systems lag behind innovation, particularly in emerging areas like digital health and AI-powered diagnostics. Keyword-based searches supplement classification approaches, capturing edge cases and novel terminology that formal systems might miss. Therefore, continuous monitoring becomes essential infrastructure, not just optional surveillance.

Standards Essential Patents

Standard Essential Patents (SEPs) create unique challenges for MedTech innovators. Wireless connectivity, data transmission protocols, and interoperability standards often incorporate patented technologies. Any device implementing these standards will potentially infringe underlying patents, regardless of independent development.

The telecommunications industry pioneered FRAND (Fair, Reasonable, and Non-Discriminatory) licensing frameworks for SEPs. But FRAND terms remain subjective, leading to disputes over appropriate royalty rates and licensing conditions. MedTech companies must budget for potential licensing costs when implementing standardised technologies.

Drawing on robust data paints a clearer picture of medical technology's contribution to both healthcare and the wider economy in Europe.

_{Oliver Bisazza, CEO of MedTech Europe}

Global Coverage Gaps

Patent rights remain territorial despite globalised markets. Protection in the United States doesn't prevent competitors from manufacturing competing products in Europe or Asia, then potentially importing through complex supply chains that might trigger infringement claims. Global MedTech markets require coordinated filing strategies across multiple jurisdictions. The Patent Cooperation Treaty system provides centralised filing for initial applications, but national phase entry decisions require careful analysis of market size, competitive threats, and enforcement environments.

The medical device industry's regulatory complexity adds another layer. Products requiring clinical trials and regulatory approval in specific markets face higher barriers to entry, making patent protection in those territories more valuable. Countries with streamlined regulatory pathways might warrant patent protection even if market size alone wouldn't justify the expense.

Challenging Weak Patents: The Invalidity Option

Not all patents deserve respect. Prior art invalidation represents a powerful tool for clearing problematic rights that block legitimate innovation. Expired patents, academic publications, conference presentations, and product demonstrations can establish invalidity defences against seemingly blocking patents.

Our focus is on ensuring that patients benefit from the earliest possible access to safe and effective medical technologies that meet their needs and deliver significant clinical benefit.

_{Lawrence Tallon, MHRA Chief Executive Officer}

Strategic patent challenges require careful cost-benefit analysis. Challenge procedures consume time and resources while outcomes remain uncertain. However, successful challenges can clear entire technology areas, creating white space for innovation, while deterring weak enforcement attempts from patent holders fishing for licensing revenue.

Building Your FTO defence

Comprehensive FTO analysis demands multi-layered approaches that combine technical searches, legal analysis, and commercial evaluation. Technical searches will identify potentially relevant patents using classification codes, keyword strategies, and inventor tracking. Legal analysis assesses infringement risk under claim interpretation principles and prosecution history limitations.
Professional patent attorneys bring essential expertise to FTO analysis, but business leaders must understand enough fundamentals to make informed strategic decisions. The goal isn't eliminating all risk but to manage risk at acceptable levels (while preserving innovation freedom).

Waypoint checklist

Your investment in a comprehensive FTO analysis will pay dividends in reduced legal risk, clearer development pathways, and sustainable competitive positioning in increasingly crowded markets.

• File your provisional patent to lock in early.
• Check granted patents in key markets for overlapping claims.
• Monitor unpublished filings that could later block your device.
• Identify licensing risks for standardised tech with SEPs.
• Find global coverage gaps to ensure no foreign patent obstructs target markets.
• Search for expired/weak patents by using prior art to challenge invalid but obstructive patents.

Need help with your FTO strategy?

The rapid pace of innovation means FTO analysis becomes an ongoing process rather than a one-time exercise. We can help ensure you take in regular updates, capture newly published applications, seek out granted patents, and understand the changes in the competitive landscape. Partners who master these complexities will gain a significant competitive advantage in bringing breakthrough technologies to the people, that help the people, that help the people.

Contact us CTA?